The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma
Open accessAbstract
Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of this patient population. In the past decade, there have been improvements in nonsurgical treatment platforms and better standardization with respect to the diagnosis and patient eligibility for liver transplant. How to navigate patients through the challenges of treatment is difficult and depends on several factors: 1) patient‐related variables such as comorbid conditions that influence treatment eligibility; 2) liver‐related variables such as Child‐Pugh score; and 3) tumor‐related variables such as size, number, pattern of spread within the liver, and vascular involvement. The objectives of this review are to put into perspective the current treatment options for patients with HCC, the unique advantages and disadvantages of each treatment approach, and the evidence that supports the introduction of sorafenib into the multidisciplinary management of HCC. CA Cancer J Clin 2012;. © 2012 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Self-citationLlovet, J. M., Ducreux, M. P., Lencioni, R. A., Bisceglie, A. M. D., Dufour, J., Greten, T. F., Raymond, É., Roskams, T., Mazzaferro, V., Bruix, J., et al. (2012) · Cited by 1,481
A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients
(1998) · Hepatology · doi:10.1002/hep.510280322 · Cited by 1,238
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Salem, R., Lewandowski, R. J., Mulcahy, M. F., Riaz, A., Ryu, R. K., Ibrahim, S., Atassi, B., Baker, T., Gates, V., Miller, F. H., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.006 · Cited by 1,074
Cammà, C., Schepis, F., Orlando, A., Albanese, M., Shahied, L., Trevisani, F., Andreone, P., Craxì, A., & Cottone, M. (2002) · Radiology · doi:10.1148/radiol.2241011262 · Cited by 851
Cancers with increasing incidence trends in the United States: 1999 through 2008
Simard, E. P., Ward, E. M., Siegel, R., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20141 · Cited by 724
Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors
Shiina, S., Tateishi, R., Arano, T., Uchino, K., Enooku, K., Nakagawa, H., Asaoka, Y., Sato, T., Masuzaki, R., Kondo, Y., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.425 · Cited by 724
Salem, R., Lewandowski, R. J., Kulik, L., Wang, E., Riaz, A., Ryu, R. K., Sato, K. T., Gupta, R., Nikolaidis, P., Miller, F. H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.049 · Cited by 650
Kudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W.-Y., Takayama, T., Yoon, J.-H., Hori, T., Kumada, H., Hayashi, N., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.007 · Cited by 570
Burrel, M., Reig, M., Forner, A., Barrufet, M., Lope, C. R. D., Tremosini, S., Ayuso, C., Llovet, J. M., Real, M. I., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.008 · Cited by 485
Duffy, J. P., Vardanian, A., Benjamin, E., Watson, M., Farmer, D. G., Ghobrial, R. M., Lipshutz, G., Yersiz, H., Lu, D. S. K., Lassman, C., et al. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e318148c704 · Cited by 445
Okuda, K. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80428-6 · Cited by 443
Stereotactic Body Radiotherapy for Primary Hepatocellular Carcinoma
Andolino, D. L., Johnson, C. S., Maluccio, M., Kwo, P., Tector, A. J., Zook, J., Johnstone, P. A. S., & Cardenes, H. R. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.04.011 · Cited by 442
Self-citationForner, A., Ayuso, C., Varela, M., Rimola, J., Hessheimer, A. J., de Lope, C. R., Reig, M., Bianchi, L., Llovet, J. M., & Bruix, J. (2009) · Cancer · doi:10.1002/cncr.24050 · Cited by 426
Yao, F. Y., Ferrell, L., Bass, N. M., Bacchetti, P., Ascher, N. L., & Roberts, J. P. (2002) · Liver Transplantation · doi:10.1053/jlts.2002.34892 · Cited by 408
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging
Sano, K., Ichikawa, T., Motosugi, U., Sou, H., Muhi, A. M., Matsuda, M., Nakano, M., Sakamoto, M., Nakazawa, T., Asakawa, M., et al. (2011) · Radiology · doi:10.1148/radiol.11101840 · Cited by 353
Gillmore, R., Stuart, S., Kirkwood, A., Hameeduddin, A., Woodward, N., Burroughs, A. K., & Meyer, T. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.007 · Cited by 324
Cárdenes, H. R., Price, T. R., Perkins, S. M., Maluccio, M., Kwo, P., Breen, T. E., Henderson, M. A., Schefter, T. E., Tudor, K., Deluca, J., et al. (2010) · Clinical and Translational Oncology · doi:10.1007/s12094-010-0492-x · Cited by 307
Self-citationPawlik, T. M., Reyes, D. K., Cosgrove, D., Kamel, I. R., Bhagat, N., & Geschwind, J.-F. H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.1021 · Cited by 304
Josep, M. L., Ducreux, M. P., Riccardo, L., et al. (2012) · European Journal of Cancer · Cited by 195
Sergi, C., Adam, S., Kahl, P., & Otto, H. F. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)81188-5 · Cited by 189
Schlesinger, S., Aleksandrova, K., Pischon, T., Fedirko, V., Jenab, M., Trepo, E., Boffetta, P., Dahm, C. C., Overvad, K., Tjønneland, A., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27645 · Cited by 185
Takuma, Y., & Nouso, K. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i12.1436 · Cited by 128
Radiofrequency ablation of hepatocellular carcinoma: Long-term outcome and prognostic factors
Yan, K., Chen, M., Yang, W., Wang, Y. B., Gao, W., Hao, C. Y., Xing, B. C., & Huang, X. F. (2007) · European Journal of Radiology · doi:10.1016/j.ejrad.2007.07.007 · Cited by 121
An overview of evidence-based management of hepatocellular carcinoma: A meta-analysis
Salhab, M., & Canelo, R. (2011) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.92023 · Cited by 116
Long-Term Outcome of Percutaneous Ablation in Very Early-Stage Hepatocellular Carcinoma
Kuang, M., Xie, X., Huang, C., et al. (2011) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1716-2 · Cited by 47
Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation
Hanje, A. J., & Yao, F. Y. (2008) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3282fc2633 · Cited by 32
Cited by
Reactive Oxygen Species (ROS)-Based Nanomedicine
Yang, B., Chen, Y., & Shi, J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00626 · Cited by 2,443
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 763
New knowledge of the mechanisms of sorafenib resistance in liver cancer
Zhu, Y.-J., Zheng, B., Wang, H.-Y., & Chen, L. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.5 · Cited by 702
Gong, N., Ma, X., Ye, X., Zhou, Q., Chen, X., Tan, X., Yao, S., Huo, S., Zhang, T., Chen, S., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0373-6 · Cited by 601
Zhu, Y., Yang, J., Xu, D., Gao, X.-M., Zhang, Z., Hsu, J. L., Li, C.-W., Lim, S.-O., Sheng, Y.-Y., Zhang, Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318419 · Cited by 419
Metadata
- Authors
- Maluccio, M., & Covey, A.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2012-10-15
- Volume
- 62
- Issue
- 6
- Pages
- 394-399
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W2129802218
- Cited by
- 840
- References
- 37
- FWCI
- 25.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.